Addex Therapeutics Ltd · SIX:ADXN

Addex Therapeutics — Investor Presentation (March 2015)

58 slides from Addex Therapeutics's investor presentation, March 2015

  1. Slide 1: Addex Corporate Presentation

    Addex Corporate Presentation March 2015

  2. Slide 2: Disclaimer

    Disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their di

  3. Slide 3: Overview and Background

    Overview and Background • Addex was founded in 2002 in Geneva, Switzerland • ADXN is traded on the SIX Swiss Stock Exchange since 2007 • Pioneering oral small molecule allosteric modulation-based drug discovery and development • Clinical stage pipeline: 2 Phase II programs, 1 Phase I ready program a

  4. Slide 4: Value drivers and competitive advantage

    Value drivers and competitive advantage Leading allosteric • Proprietary 85,000 knowledge-based HTS library z • Proprietary HTS high-fidelity pharmacology systems drug discovery platform • Deep allosteric know-how & expertise • Proven mechanism, that has led to marketed products Validated therapeuti

  5. Slide 5: Clinical stage pipeline

    Clinical stage pipeline NAM = Negative Allosteric Modulator 5 PAM = Positive Allosteric Modulator

  6. Slide 6: Preclinical stage pipeline

    Preclinical stage pipeline NAM = Negative Allosteric Modulator 6 PAM = Positive Allosteric Modulator

  7. Slide 7: Discovery programs

    Discovery programs TARGET R&D STAGE INDICATION ADDITIONAL INFORMATION HTS Performed G Neuroprotection acheived through modulation of mGluR3 PAM Screening Hits Neuroprotection in PD . growth factors, mGluR8 activation has been linked to anxiety/GAD, HTS Performed mGluR8 PAM P . Exploratory target neu

  8. Slide 8: Board, management and advisors

    Board, management and advisors • Board: – Professor Vincent Lawton, CBE • formerly Managing Director and Vice President - Europe, Merck Sharp & Dohme UK (MSD) Ltd, Member of the Board of the UK Medicines & Healthcare Product Regulatory Agency (MHRA) • Management: – Tim Dyer, CEO/CFO – Sonia Poli, CS

  9. Slide 9: Financials and stock

    Financials and stock • Cash runway through 2017 – CHF1.8M million in cash as of 31 December 2014 – CHF2.8M PIPE executed on 6 March 2015 • Traded on SIX Swiss Exchange: ADXN (ISIN:CH0029850754) • 11,699,612 shares outstanding (13 million fully diluted) – Herculis Partners holds 4.1% • Analysts cover

  10. Slide 10: Summary

    Summary • Key strategic objectives − Secure resources to advance clinical pipeline − Collaborate with Industry / governments / academia / patient advocacy groups to advance clinical / preclinical / discovery programs • Sufficient financial resources & team to execute key strategy objectives • Diprag

  11. Slide 11: Dipraglurant mGluR5 NAM

    Dipraglurant mGluR5 NAM fo} Q xe) [o} OQ e fe} 11

  12. Slide 12: Dipraglurant (ADX48621) overview

    Dipraglurant (ADX48621) overview • A negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5) discovered at Addex in 2003 • Highly selective, oral, brain penetrant, small molecule, active in several preclinical models of anxiety, depression, Parkinson’s disease (PD) and

  13. Slide 13: Dipraglurant in Parkinson's Disease

    Dipraglurant in Parkinson’s Disease 13

  14. Slide 14: Parkinson's disease and PD-LID

    Parkinson’s disease and PD-LID • There are currently over 4 million people suffering from Parkinson’s disease (PD) in the US, 5EU, China and India – the patient universe is set to continue to grow due to improved awareness and diagnosis (particularly in China and India) • Parkinson’s disease (PD) is

  15. Slide 15: Basal ganglia circuit and changes in Parkinson's disease

    Basal ganglia circuit and changes in Parkinson’s disease Circuit in healthy basal ganglia Circuit in the basal ganglia affected by Parkinson’s disease Denervation of the substantia nigra and loss of dopaminergic input into the striatum causes over-activity of the indirect output pathway and under-ac

  16. Slide 16: Rationale for targeting mGluR5 inhibition in Parkinson's disease

    Rationale for targeting mGluR5 inhibition in Parkinson’s disease L-Dopa induced dyskinesia (PD-LID) • Denervation of dopaminergic striatal neurons within the SNc combined with the non-physiological, pulsatile, stimulation of dopamine receptors induce profound pathological changes which result in dys

  17. Slide 17: Treatment options for PD-LID and development pipeline

    Treatment options for PD-LID and development pipeline • Management of the L-Dopa dose/ extended release formulation; L-Dopa sparing concept – Balance good motor symptoms controls against occurrence of LID – Sustained release formulation of L-Dopa might even prolong the dyskinesia episodes – Infusion

  18. Slide 18: Effect of dipraglurant in the haloperidol-induced catalepsy test

    Effect of dipraglurant in the haloperidol-induced catalepsy test (a model of PD in rats) • In this model, haloperidol, a dopamine receptor antagonist, was administered to induce catalepsy, characterized by hypokinesia and rigidity. Anti-parkinsonian drugs decrease the catalepsy induced by haloperido

  19. Slide 19: Dipraglurant reduced dystonia as well as chorea in the macaque PD-LID model

    Dipraglurant reduced dystonia as well as chorea in the macaque PD-LID model 15 15 median dystonia (0-2 hr) median chorea (0-2 hr) **p <0.01 10 * p<0.05 10 ** * 5 5 0 0 vehicle 3 10 30 vehicle 3 10 30 dipraglurant (mg/kg) dipraglurant (mg/kg) All received L-Dopa All received L-Dopa • Dipraglurant sig

  20. Slide 20: Summary of dipraglurant clinical development

    Summary of dipraglurant clinical development • Initial Phase I program of dipraglurant successful − Three studies: single & multiple ascending doses, gender/food effects − 132 subjects studied to date, including 30 older subjects − Pharmacokinetics of dipraglurant immediate release formulation (IR)

  21. Slide 21: EU and US Phase IIa dipraglurant trial for PD-LID

    EU and US Phase IIa dipraglurant trial for PD-LID • Primary objective: safety & tolerability • Secondary objective: • Dipraglurant taken exploratory efficacy with levodopa • Objective evaluation in the clinic • Dipraglurant titration on day 1 and 14 & 28 • Randomized, – Trained observer scores doubl

  22. Slide 22: Primary objective of Phase IIa study achieved: safety and tolerability

    Primary objective of Phase IIa study achieved: dipraglurant 50 and 100 mg doses demonstrated safety and tolerability in PD patients • There were no treatment effects seen on any of the safety monitoring variables • No treatment effects on 12-lead ECG, HR, BP (sitting and standing), haematology and b

  23. Slide 23: Secondary objective of Phase IIa study achieved

    Secondary objective of Phase IIa study achieved: clinical effect and dose characterization • Dipraglurant achieved significant reduction in dyskinesia severity – Reduction in mAIMS (modified Abnormal Involuntary Movement Scale) both at peak levodopa concentrations and area under curve over the three

  24. Slide 24: Results of Phase IIa study shows that dipraglurant reduces LID severity

    Results of Phase IIa study shows that dipraglurant reduces LID severity • Dipraglurant reduced peak dose mAIMS (90 min after dipra placebo dosing) with a dose proportional effect • Dipraglurant reduced dyskinesia severity for the full 3 35% * hour post-dosing period - mAIMS area under the curve 30%

  25. Slide 25: Patient and Clinician Global Impression of Change

    Patient and Clinician Global Impression of Change • PGIC and CGIC: greater improvement in dyskinesia with dipraglurant according to patients (65.3% vs 58.4% pbo, p = ns), and clinicians (71.2% vs 49.6% p<0.05) Global Impression Change: Dyskinesia 50% 45% 40% 35% 30% % of patients PGIC ADX PGIC PBO 2

  26. Slide 26: Patient-reported measurable clinical effects: Time in Off

    Patient-reported measurable clinical effects: Time in “Off” change from baseline Change in "Off" time (min/day) 40 20 0 minutes per day Week 1 Week 2 Week 3 Week 4 Dipraglurant N = 52 -20 Placebo n = 24 -40 -60 -80 • Dipraglurant treatment caused no increase in “off” time • At week 4 “off” time decr

  27. Slide 27: Patient-reported measurable clinical effects: on time with no dyskinesia

    Patient-reported measurable clinical effects: “on time” with no dyskinesia 50 mg dose level 100mg dose level • Dipraglurant treatment increased “On time” with no dyskinesia to 2.3 hours by week 4 • MPTP macaque data indicates a similar effect on prolongation of L-DOPA efficacy • Dipraglurant is also

  28. Slide 28: Dipraglurant effect correlates with its plasma concentration

    Dipraglurant effect in reducing PD-LID correlates with its plasma concentration: IC50 = 1317 ng/mL Plasma concentration - PK PK – PD correlation mAIMS - PD 28

  29. Slide 29: Summary of dipraglurant in Parkinson's disease/PD-LID

    Summary of dipraglurant in Parkinson’s disease/PD-LID • Anti-dyskinetic effect: – MPTP monkey model of PD-LID – PD-LID patients • Adjunctive treatment of PD motor fluctuations: – Haloperidol catalepsy model – Increased anti-parkinsonian effect in MPTP monkey model – Tendency to improve on-time in PD

  30. Slide 30: Recent literature on the role of mGluR5 NAMs in the treatment of dyskinesias

    Recent literature on the role of mGluR5 NAMs in the treatment of dyskinesias • Finlay C, Duty S. Therapeutic potential of targeting glutamate receptors in Parkinson's disease. J Neural Transm. 2014 Feb 21. [Epub ahead of print] PubMed PMID: 24557498. • Rascol O, Fox S, Gasparini F, Kenney C, Di Paol

  31. Slide 31: Dipraglurant in Dystonia

    Dipraglurant in Dystonia fo} Q xe) [o} OQ e fe} 31

  32. Slide 32: Dystonia

    Dystonia • Dystonia are a heterogeneous group of movement disorders characterized by involuntary muscle contractions that force the body into abnormal, sometimes painful, movements and positions (postures) • Dystonia can affect a single part of the body (focal), multiple areas (segmental) or the who

  33. Slide 33: Dystonia and rationale for targeting mGluR5 inhibition

    Dystonia and rationale for targeting mGluR5 inhibition • Dystonia are neuro-functional rather neuro- degenerative disorder. • Common altered features include: – subtle alterations in neuronal connectivity/ function – altered synaptic communication within the basal ganglia • Aberrant or maladaptive b

  34. Slide 34: Dystonia treatments and development pipeline

    Dystonia treatments and development pipeline • Physical therapy and massage, including sensory biofeedback techniques • Deep brain stimulation for inherited/idiopathic dystonias reduces severity of symptoms by approximately 50%, but significantly varies between individuals with DYT1 patients benefit

  35. Slide 35: Preclinical and clinical efficacy of dipraglurant in dystonia

    Preclinical and clinical efficacy of dipraglurant in dystonia • Phase IIa studies in PD-LID patients • PD-LID MPTP monkey (drug induced dyskinesia with features of dystonia) • DYT-1 mouse model (genetic dystonia) • Tottering mouse model (paroxysmal dystonia) 35

  36. Slide 36: Preclinical and clinical efficacy of dipraglurant in dystonia

    Preclinical and clinical efficacy of dipraglurant in dystonia Dipraglurant normalises altered synaptic transmission observed in the striatum of DYT1 mice –it also partially restored a normal LTD in striatal MSNs after repeated treatment (data not shown) Sciamanna et al Neuropharmacology 2014 36

  37. Slide 37: Dipraglurant development plans - overview

    Dipraglurant development plans - overview • Ongoing: – Open label PET imaging receptor occupancy trial to support dose selection for Phase IIb • In preparation & financed: – Clinical pharmacology study – IR/ER – Investigator led Phase II POC trial to explore therapeutic potential in dystonic patient

  38. Slide 38: Dipraglurant summary and conclusions

    Dipraglurant summary and conclusions • Strong rationale to develop dipraglurant for treatment in PD-LID: – Robust phase IIa POC results in which immediate release formulation of dipraglurant has shown an optimal PK and PD profile for PD-LID – Novartis departure from field leaves dipraglurant as firs

  39. Slide 39: ADX71441 - GABAB R positive allosteric modulator

    ADX71441-GABABR positive allosteric modulator 39

  40. Slide 40: Oral GABAB receptor PAM (ADX71441)

    Oral GABAB receptor PAM (ADX71441) • ADX71441 is a novel, first-in-class, oral, small molecule activator of gamma-aminobutyric acid subtype B (GABAB) receptor functioning through positive allosteric modulation (PAM) • Activation of GABAB receptor is preclinically, clinically & commercially validated

  41. Slide 41: ADX71441 in Charcot-Marie-Tooth type 1A neuropathy

    ADX71441 in Charcot-Marie-Tooth type 1A neuropathy 41

  42. Slide 42: Rationale for developing ADX71441 in CMT1A

    Rationale for developing ADX71441 in CMT1A • Charcot Marie Tooth (CMT) disorder is one of the most common inherited neuropathy and a duplication of the peripheral myelin protein 22 gene causes the most frequent subtype CMT1A. • CMT1A affects approximately 1 in 5,000 people worldwide. • Patients deve

  43. Slide 43: GABAB and CMT1A

    GABAB and CMT1A • GABAB has been shown to regulate the production of PMP-22 • Gene duplication of the pmp22 gene causes over production of peripheral myelin protein-22 (PMP-22), causing the structure and function of the myelin sheath to be abnormal. Cross Section of Axons Healthy 27 year old patient

  44. Slide 44: CMT1A treatments and development pipeline

    CMT1A treatments and development pipeline • Non-invasive therapies (e.g. exercise, physiotherapy, orthotics). • Surgery to straighten toes, lengthen heel cords or lower arches. • Drugs used off-label for the treatment of CMT1A include: – Anticonvulsants (e.g. Clonazepam and Gabapentin) to treat the

  45. Slide 45: GABAB R activation therapy with ADX71441 in CMT rats

    GABABR activation therapy with ADX71441 in CMT rats • CMT rats showed an overexpression of pmp22 mRNA, axonal loss and reduced grip strength reflecting typical CMT1A features • In a comparative study with baclofen in CMT1A rats, ADX71441 significantly reduced pmp22 mRNA at 3mg/kg and 6 mg/kg p.o. (0

  46. Slide 46: GABAB R activation therapy with ADX71441 in CMT rat model

    GABAB R activation therapy with ADX71441 in CMT rat model • ADX71441 therapy (9 weeks) in CMT rats down regulated pmp22 mRNA, reduced the amount of hypomyelinated axons and increased compound muscle action potentials in peripheral nerves • ADX71441 therapy (9 weeks) in wild-type rats did not affect

  47. Slide 47: ADX71441 in addiction of nicotine and alcohol

    ADX71441 in addiction of nicotine and alcohol 47

  48. Slide 48: Rationale for developing ADX71441 in addiction

    Rationale for developing ADX71441 in addiction • GABA is the major inhibitory neurotransmitter in the brain and is implicated in the modulation of central reward processes. • Administration of GABAB receptor agonists or positive modulators decreased self- administration of various drugs of abuse. •

  49. Slide 49: GABAB R mechanism of action in alcohol addiction

    GABABR mechanism of action in alcohol addiction Dopaminergic ventral tegmental area (VTA) neurons that project to the nucleus accumbens (NAc) are under tonic inhibition by GABAergic interneurons within the VTA. GABA release from these neurons is in turn under negative regulation by the mu-opioid rec

  50. Slide 50: Alcohol addiction treatments and development pipeline

    Alcohol addiction treatments and development pipeline • Rehabilitation centres and mutual aid groups (e.g. Alcoholics anonymous). • Drugs such as: – Acamprosate (NMDA antagonist) prevents glutamatergic stimulation as well as activating GABA. Efficacious in combination with naltrexone. – Dilsulfiram

  51. Slide 51: ADX71441 preclinical validation in alcohol consumption model

    ADX71441 preclinical validation in alcohol consumption model Cumulative intake of ethanol (g) • ADX71441 resulted in robust and dose-dependent reductions of alcohol consumption in male mice with MED of 10 mg/kg • At 10 and 30 mg/kg of ADX71441 the percentage change in alcohol consumption vs. vehicle

  52. Slide 52: GABAB receptor mechanism of action in nicotine addiction

    GABAB receptor mechanism of action in nicotine addiction Dopaminergic neurons in the VTA receive two main excitatory inputs from both cholinergic and glutamatergic neurons both of which can be stimulated by nicotine. A number of nicotinic receptors are present on the dopaminergic neurons. These neur

  53. Slide 53: Nicotine addiction treatments and development pipeline

    Nicotine addiction treatments and development pipeline • Support groups and counselling • Drugs such as: - Nicotine replacement therapy such as gum, arm patch, lozenges, nasal spray (prescription) and inhaler (prescription) - Bupropion (antidepressant) used for smoking cessation. Multiple adverse ef

  54. Slide 54: ADX71441: evaluation on precipitated nicotine withdrawal model in mice

    ADX71441: evaluation on precipitated nicotine withdrawal model in mice Model of mecamylamine precipitated physical and affective withdrawal signs in mice rendered dependent on chronic nicotine • ADX71441 significantly reduced somatic signs in nicotine-withdrawn mice in a dose-dependent manner with 1

  55. Slide 55: ADX71441 summary and conclusion

    ADX71441 summary and conclusion • Strong rationale to develop a GABAB PAM that has a differentiated profile to baclofen: - GABAB PAM is clinically validated by data generated with baclofen, an orthosteric agonist of the GABAB receptor - ADX71441 has a differentiated preclinical profile to baclofen:

  56. Slide 56: Janssen partnership ADX71149: mGluR2 PAM

    Janssen partnership ADX71149: mGluR2 PAM Significant potential in treating CNS disorders 56

  57. Slide 57: Overview of Janssen partnership (ADX71149)

    Overview of Janssen partnership (ADX71149) • ADX71149 is a highly selective oral brain penetrant small molecule metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM) discovered in collaboration with Janssen Pharmaceuticals Inc.(JPI) • mGluR2 PAM is validated in multiple indi

  58. Slide 58: Allosteric modulators for human health

    Allosteric modulators for human health www.addextherapeutics.com 58

Addex Therapeutics — Investor Presentation (March 2015) on 6ix